a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, LYRA has been closely correlated with ROQAF. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if LYRA jumps, then ROQAF could also see price increases.
Ticker / NAME | Correlation To LYRA | 1D Price Change % | ||
---|---|---|---|---|
LYRA | 100% | -8.95% | ||
ROQAF - LYRA | 85% Closely correlated | N/A | ||
GLYC - LYRA | 75% Closely correlated | -0.65% | ||
EYPT - LYRA | 39% Loosely correlated | -2.51% | ||
HSTC - LYRA | 29% Poorly correlated | N/A | ||
BCYC - LYRA | 27% Poorly correlated | -2.76% | ||
More |
Ticker / NAME | Correlation To LYRA | 1D Price Change % |
---|---|---|
LYRA | 100% | -8.95% |
LYRA (2 stocks) | 94% Closely correlated | -0.31% |
therapeutics (53 stocks) | 10% Poorly correlated | -2.40% |
treatment (56 stocks) | 9% Poorly correlated | -1.02% |
diseases (41 stocks) | 7% Poorly correlated | -1.10% |